Global Perspectives on Lymphoma in 2022 and Beyond

Global clinical experts discuss perspectives on current treatment strategies and emerging therapies for lymphomas, including CLL, SLL, FL, T-cell, MZL, MCL, Waldenström macroglobulinemia, and DLBCL.

September 8 and 9, 2022
Purchase Report

FACULTY CHAIR

Brad S. Kahl, MD

Washington University School of Medicine, St. Louis, MO, USA

Faculty Members

Matthew Lunning, DO, FACP
University of Nebraska Medical Center, Omaha, NE, USA

John Allan, MD
Weill Cornell Medicine, New York, NY, USA

Peter Martin, MD
Weill Cornell Medicine, New York, NY, USA

Stefan Barta, MD, MS, MRCPCUK
Penn Medicine, London, United Kingdom

Matthew Matasar, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Georg Hess, MD
Johannes Gutenberg University, Mainz, Germany

Pier Luigi Zinzani, MD, PhD
University of Bologna Institute of Hematology and Medical Oncology, Bologna, Italy

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • Advances in CLL/SLL
  • Role of Fixed-Duration and MRD-Guided Strategies in CLL
  • Advances in Follicular Lymphoma
  • Advances in T-Cell Lymphoma
  • Advances in Marginal Zone Lymphoma
  • Advances in DLBCL/Aggressive B-Cell Lymphoma
  • Advances in Mantle Cell Lymphoma
  • Advances in Waldenström Macroglobulinemia

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.